Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Clinical Trial
Share your love
David Almeida, MD, MBA, PhD, advances ophthalmic training with near real surgical specimens | Ophthalmology Times
David Almeida, MD, MBA, PhD, highlights near real surgical systems (NRSS), providing ophthalmologists with anatomically accurate models that replicate real surgical scenarios for training, research, and device development. (Image credit: AdobeStock/Iurii) A vitreoretinal surgeon and clinician-scientist with Erie Retina Research…
Timothy Lai on the SALWEEN trial
Photo of Timothy Lai, MD, at EURETINA 2025 in Paris, France Timothy Lai, a clinical professor honorary at the Department of Ophthalmology and Visual Sciences at the Chinese University of Hong Kong, presented the one-year data from the Salween study…
Sruthi Arepalli, MD, spotlights a deep-dive orbital tour of the eye
To learn more about or to register for EyeCon 2025, click here. Set against the backdrop of a scenic Florida coastline and a growing emphasis on cross-specialty collaboration in eye care, the Ophthalmology Times and Optometry Times EyeCon® 2025 conference is…
Beacon Therapeutics reports positive phase 2 results for gene therapy in X-linked retinitis pigmentosa
(Image Credit: AdobeStock/Dmitrii Kotin) Beacon Therapeutics recently revealed topline data results for 2 of the company’s phase 2 trials—SKYLINE and DAWN, both investigating laruparetigene zovaparvovec (laru-zova) in patients with X-linked retinitis pigmentosa (XLRP).1 The data was presented during the 2025…
Positive topline data announced from AVONELLE-X and SALWEEN trials
(Image credit: ©pressmaster/AdobeStock) Roche recently announced new data from the AVONELLE-X and SALWEEN trials of Vabysmo (faricimab).1 These trial data were presented at the 25th European Society of Retina Specialists (EURETINA) Annual Congress held September 4-7 in Paris. Positive safety,…
Amir Kashani on biomarkers for Alzheimer disease
(Image credit: AdobeStock/Pixel Matrix) Amir H. Kashani, MD, PhD, is a professor of ophthalmology at the Wilmer Eye Institute in Johns Hopkins University in Baltimore, Maryland. In an interview with Ophthalmology Times, Kashani discussed a research paper on OCT-A angiography’s…
Opus Genetics doses first patient in LYNX-3, phase 3 trial of phentolamine ophthalmic solution 0.75%
(Image Credit: AdobeStock/svetlanais) Opus Genetics has dosed the first patient in LYNX-3, its pivotal phase 3 clinical trial of phentolamine ophthalmic solution 0.75% in treating significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision. Night-vision disturbances, which…
Celltrion announces phase 3 trial data for EYDENZELT
(Image credit: ©HockleyM2) Celltrion recently announced 52-week findings from its global phase 3 clinical trial for its ophthalmic treatment candidate, EYDENZELT.1 EYDENZELT, a biosimilar of EYLEA (aflibercept), is Celltrion’s ophthalmic treatment candidate for the treatment of multiple retinal diseases, including…
Alcon completes acquisition of LumiThera
(Image Credit: AdobeStock/Timon) Alcon has completed its planned acquisition of LumiThera, Inc, which was announced earlier in July of this year.1,2 According to Alcon, the acquisition includes the noninvasive Valeda photobiomodulation (PBM) device for the treatment of early and intermediate dry…
Ashvattha reports positive phase 2 results for migaldendranib in DME and nAMD
(Image Credit: AdobeStock) Ashvattha Therapeutics shared positive topline data from its phase 2 study of migaldendranib (MGB) for the treatment of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). The topline end-of-study results were announced at the 25th…